Malignant Tumors

Oncology
3
Pipeline Programs
1
Companies
3
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
3
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

LaNova Medicines
LaNova MedicinesChina - Shanghai
3 programs
3
LM-299Phase 1/21 trial
LM-350 for injectionPhase 1/21 trial
LM101Phase 1/21 trial
Active Trials
NCT06650566RecruitingEst. Jul 2027
NCT07112222RecruitingEst. Jun 2030
NCT05615974RecruitingEst. Jan 2028

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
2030
LaNova MedicinesLM-350 for injection
LaNova MedicinesLM-299
LaNova MedicinesLM101

Clinical Trials (3)

NCT07112222LaNova MedicinesLM-350 for injection

A Study of LM-350 in Subjects With Advanced Solid Tumours

Start: Aug 2025Est. completion: Jun 2030
Phase 1/2Recruiting

Study of LM-299 in Subjects Advanced Malignant Tumors

Start: Oct 2024Est. completion: Jul 2027
Phase 1/2Recruiting

A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors

Start: Jan 2023Est. completion: Jan 2028
Phase 1/2Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 actively recruiting trials
1 companies competing in this space